These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36142299)

  • 1. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
    Kang J; Guo Z; Zhang H; Guo R; Zhu X; Guo X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells.
    Yeo CD; Kim YA; Lee HY; Kim JW; Lee SH; Kim SJ; Kwon SS; Kim YH; Kim SC
    Exp Lung Res; 2017 Feb; 43(1):29-37. PubMed ID: 28394654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
    Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
    Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
    Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
    Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
    Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
    Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
    Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
    Guo XF; Li SS; Zhu XF; Dou QH; Liu D
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
    Ma W; Zhang T; Pan J; Shi N; Fan Q; Wang L; Lu SH
    Oncol Rep; 2014 Oct; 32(4):1601-9. PubMed ID: 25175038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
    Camirand A; Zakikhani M; Young F; Pollak M
    Breast Cancer Res; 2005; 7(4):R570-9. PubMed ID: 15987464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
    Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
    Saxena NK; Taliaferro-Smith L; Knight BB; Merlin D; Anania FA; O'Regan RM; Sharma D
    Cancer Res; 2008 Dec; 68(23):9712-22. PubMed ID: 19047149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
    BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
    Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
    Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
    Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.